What Makes Honey 'Medical-Grade'? Standards, MGO, and Sterility
In 2025, researchers including Dr. Ferhat Öztürk published a consensus definition of “medical-grade honey.” Organic sourcing, gamma sterilization, measured potency — what the standard requires and why each element matters.
“Medical-grade” gets printed on a lot of jars. In 2025, a group of researchers — including Dr. Ferhat Öztürk as co-author — published a consensus paper in the Journal of Wound Care that finally pins the term down: “Medical-grade honey: its definition and refined standards.” ghmap.io covers the field's agenda, and definitions like this one are market infrastructure: the moment a term is standardized, products can be compared, regulated, procured — and sold. Here is what the standard says, why each element exists, and how it connects to the products hospitals actually buy.
The 2025 definition
- The paper: Peters, Majtan, Mossialos, Szweda, Mateescu, Ozturk, Wagener, and Cremers — “Medical-grade honey: its definition and refined standards,” Journal of Wound Care, 2025, 34(6):412–423. DOI: 10.12968/jowc.2024.0206.
- Organic production — clean, traceable sourcing as the starting point.
- Gamma sterilization (ISO 11137) — sterility achieved without destroying bioactivity.
- Clinical safety benchmarks — documented safety criteria a medical product must meet.
- Physicochemical criteria — measured antibacterial activity and composition, not marketing claims.
MGO and the potency question
Much of the medical-honey conversation revolves around Manuka honey from New Zealand — and around MGO, methylglyoxal, the naturally occurring compound strongly associated with Manuka's non-peroxide antibacterial potency. The consensus logic is straightforward: whatever the floral source, potency must be measured, not promised. That is the same instinct behind Öztürk's Texas screening work, which benchmarked local honeys against Manuka to find U.S. varieties that could compete on measured antibacterial power.
Sterility without killing the science
Raw honey is not sterile — and a wound dressing must be. Gamma irradiation per ISO 11137 is the consensus answer because it achieves sterility while preserving the bioactivity that makes honey interesting in the first place; heat sterilization would destroy the very compounds doing the work. But sterilization is only as good as the barrier that keeps it sterile: in 2025 the FDA logged Class II recalls of MediHoney gel (January, a packaging defect) and MediHoney hydrogel sheet dressings (August, packaging failures risking sterile-barrier breach). The standard does not end at the irradiator — it ends at the patient's skin.
Checklist
The medical-grade checklist
- Organic, traceable sourcing
- Gamma sterilization per ISO 11137
- Documented clinical safety benchmarks
- Measured physicochemical criteria — potency, not promises
- Manufacturing quality that protects the sterile barrier
Frequently asked questions
Checklist
Short answers
- Who defined “medical-grade honey”? A 2025 consensus paper in the Journal of Wound Care, co-authored by Dr. Ferhat Öztürk, refined the definition.
- What is MGO? Methylglyoxal — a naturally occurring compound strongly associated with Manuka honey's antibacterial potency; standards demand measured activity, not just a floral name.
- Does sterilization destroy honey's healing properties? Gamma sterilization per ISO 11137 is chosen precisely because it achieves sterility while preserving bioactivity.
- How is this regulated? Honey wound dressings are medical devices cleared via FDA 510(k), product code FRO; a January 2025 review counted more than twenty cleared honey-based wound products.
- What is changing in Europe? The EU's Medical Device Regulation is raising the evidence and safety bar for natural-product devices — a shift the 2025 consensus paper discusses.
If you are bringing a natural-product innovation toward a first market — first clearance, first distributor, first hospital pilot — a ghmap.io country-intelligence brief maps your stages. See the link below.
Next step
Bringing a natural-product device toward a first market? ghmap.io country intelligence maps the regulatory pathway, distribution channels, and reimbursement landscape — country by country. Planning conversations, not approval services and not outcome guarantees.
Get a market-entry brief
